Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report

MET exon 14 skipping mutation (METex14m) is rare and occurs in approximately 1-4% of all non-small cell lung cancer (NSCLC) patients and approximately 2.8% of resected stage I-III NSCLC patients. Savolitinib is an oral, potent and highly selective type Ib MET inhibitor, which has been shown to be pr...

Full description

Bibliographic Details
Main Authors: Meng Fu, Chun-Mei Feng, Da-Qing Xia, Zi-Mei Ji, Huai-Ling Xia, Na-Na Hu, Zai-Jun Leng, Wang Xie, Yuan Fang, Le-Jie Cao, Jun-Qiang Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
savolitinib
MET exon 14 skipping
neoadjuvant therapy
non-small cell lung cancer
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.954886/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.954886/full

Similar Items